{"id":"https://openalex.org/W4302360171","doi":null,"title":"[Iressa (gefitinib)].","display_name":"[Iressa (gefitinib)].","publication_year":2003,"publication_date":"2003-08-01","ids":{"openalex":"https://openalex.org/W4302360171","pmid":"https://pubmed.ncbi.nlm.nih.gov/12938261"},"language":"ja","primary_location":{"id":"pmid:12938261","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12938261","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gan to kagaku ryoho. Cancer & chemotherapy","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113521833","display_name":"Shoji Kudoh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I80188885","display_name":"Nippon Medical School","ror":"https://ror.org/00krab219","country_code":"JP","type":"education","lineage":["https://openalex.org/I80188885"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shoji Kudoh","raw_affiliation_strings":["Fourth Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fourth Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan","institution_ids":["https://openalex.org/I80188885"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110199773","display_name":"Akinobu Yoshimura","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Akinobu Yoshimura","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5011533142","display_name":"Akihiko Gemma","orcid":"https://orcid.org/0000-0003-0762-2737","observed_orcids":["https://orcid.org/0000-0003-0762-2737"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Akihiko Gemma","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.56552112,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"30","issue":"8","first_page":"1079","last_page":"84"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":1.0},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.7179999947547913},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.968999981880188},{"id":"https://openalex.org/keywords/chemoresistance","display_name":"chemoresistance","score":0.6769999861717224},{"id":"https://openalex.org/keywords/interstitial-lung-disease","display_name":"interstitial lung disease","score":0.9950000047683716},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7549999952316284},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.6610000133514404},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.7559999823570251},{"id":"https://openalex.org/keywords/personalized-treatment","display_name":"personalized treatment","score":0.859000027179718}],"concepts":[{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.9979268312454224},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.6525007486343384},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6310509443283081},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5977292060852051},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4927366077899933},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4772914946079254},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.44693902134895325},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4443248212337494},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4187503159046173},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2593019902706146},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2365228235721588}],"mesh":[{"descriptor_ui":"D000077156","descriptor_name":"Gefitinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004815","descriptor_name":"Epidermal Growth Factor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":1,"locations":[{"id":"pmid:12938261","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12938261","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gan to kagaku ryoho. Cancer & chemotherapy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9907000064849854}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1996253154","https://openalex.org/W2084970235","https://openalex.org/W1979565078","https://openalex.org/W2443994767","https://openalex.org/W1994858050","https://openalex.org/W2020779524","https://openalex.org/W1998962333","https://openalex.org/W2076717138","https://openalex.org/W2147037760","https://openalex.org/W2385026204"],"abstract_inverted_index":{"Gefitinib":[0],"is":[1,10,55,90],"an":[2,94],"epidermal":[3],"growth":[4],"factor":[5],"receptor":[6],"(EGFR)":[7],"inhibitor":[8],"that":[9],"reported":[11,34],"to":[12,35,57,62,73],"be":[13,104,106],"well":[14],"tolerated":[15],"and":[16,61],"active":[17],"in":[18,44],"patients":[19],"with":[20,101],"chemotherapy-resistant":[21],"non":[22],"small":[23],"cell":[24],"lung":[25,42],"cancer.":[26],"On":[27],"the":[28],"other":[29],"hand,":[30],"gefitinib":[31,75,89,102],"was":[32],"also":[33,105],"produce":[36],"a":[37],"severe":[38],"adverse":[39],"event,":[40],"interstitial":[41],"disease,":[43],"less":[45],"than":[46],"2%":[47],"of":[48,82,98],"treated":[49],"patients.":[50],"Given":[51],"these":[52],"circumstances,":[53],"it":[54],"important":[56],"evaluate":[58,74],"this":[59,77],"drug":[60],"establish":[63],"its":[64],"use":[65],"clinically.":[66],"We":[67],"do":[68],"not":[69],"have":[70],"sufficient":[71],"data":[72],"at":[76],"time.":[78],"Phase":[79],"III":[80],"study":[81],"second/third":[83],"line":[84],"or":[85],"maintenance":[86],"therapy":[87,100],"using":[88],"required":[91],"for":[92],"such":[93],"evaluation.":[95],"The":[96],"development":[97],"individualized":[99],"might":[103],"required.":[107]},"counts_by_year":[{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2022-10-06T00:00:00"}